Myeloma: Pomalidomide, Bortezomib And Dexamethasone

Myeloma: pomalidomide, bortezomib and dexamethasone

VJHemOnc – Video Journal of Hematology & HemOnc

UK practice: pomalidomide in patients resistant to lenalidomide

VJHemOnc – Video Journal of Hematology & HemOnc

OPTIMISMM study update

VJHemOnc – Video Journal of Hematology & HemOnc

The impact of bortezomib dose adjustment in the OPTIMISMM study

VJHemOnc – Video Journal of Hematology & HemOnc

The promise of pomalidomide-backbone combinations for R/R multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Real-world safety & efficacy of isatuximab-pomalidomide-dexamethasone in R/R multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Pomalidomide plus dexamethasone for R/R multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma

Elotuzumab, pomalidomide, and dexamethasone for advanced myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to...

OPTIMISMM: PVd for lenalidomide-refractory myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Bortezomib and dexamethasone after ASCT for high-risk MM

VJHemOnc – Video Journal of Hematology & HemOnc

OPTIMISMM trial for refractory multiple myeloma

Apollo: pomalidomide plus dexamethasone, with/without daratumumab in R/R MM

VJHemOnc – Video Journal of Hematology & HemOnc

Pomalidomide in Multiple Myeloma

Trial results and drug combinations for bortezomib in multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Update on the Phase 3 OPTIMISMM trial

International Myeloma Foundation

Comment: Addition of ixazomib to pomalidomide + dexamethasone improves survival for MM patients

Triplet Regimens With Pomalidomide in Patients With Multiple Myeloma

Targeted Oncology

Phase III study of isatuximab, pomalidomide, and low-dose dexamethasone in pts with RRMM

International Myeloma Foundation